Those in the lowest quartile for MCS were also at higher risk of death (HR 2.30, 95% CI 1.64, 3.22) and hospitalisation (HR 1.40, p < 0.001).
In univariate analyses, overweight and obese patients had more favourable long-term outcomes in terms of all-cause death (HR: 0.72, 95% CI 0.63 to 0.82 and HR: 0.61, 95% CI 0.51 to 0.74, respectively) and cardiac death (HR: 0.77, 95% CI 0.63 to 0.94 and HR: 0.73, 95% CI 0.56 to 0.95, respectively).
HPV positivity was associated with a 78% reduction in death rate (HR 0.22) and a 75% reduction in rate of progression, relapse or death (HR 0.25).
Patients with CKD had an increased risk of death (HR 2.50 (95% CI 1.23 5.00, p = 0.009) with the early strategy (Fig. 1).
Patients with higher PLD1 expression presented a higher risk of death (HR = 3.3049, 95% CI = 1.213 6.375, P < 0.05) (Tables S1 and S2).
After adjustments, AKI was not associated with an increased hazard of time to death (HR 1.02; 95% CI 0.83 1.26, p = 0.831) (Additional file 1: Table S3).
Active chronic graft-versus-host disease was associated with cardiovascular death (HR, 4.0; 95% confidence interval, 1.1 to 14.7); risk was otherwise similar between autologous versus allogeneic HCT recipients.
Measures of mortality included hazard rate/ratio of death (HR), life expectancy (LE), mortality rate (MR), odds ratio for mortality (OR), relative conditional survival (RCS), relative survival ratio (RSR), standardized mortality ratio (SMR), and standardized proportionate mortality ratio (SPMR).
We found patients treated at a LVC had an 18% increased risk of death (HR = 1.18, p<0.001).
SYS cases with a tumor classified as having a poor outcome had significantly increased risk for suffering a prostate cancer-specific death (HR = 2.5, 95% CI: 1.5 4.4).
SYS cases whose tumor classified as having a poor outcome had significantly increased hazard of suffering a prostate cancer-specific death (HR = 2.3, 95% CI: 1.3 4.2).
